- Home
- Automated
- List of product information
- MEFRIL-250 CAPSULE 250 MG [SIN10125P]
MEFRIL-250 CAPSULE 250 MG [SIN10125P]
Active ingredients: MEFRIL-250 CAPSULE 250 MG
Last updated 26 October 2025
On this page
Product Info
MEFRIL-250 CAPSULE 250 MG
[SIN10125P]
Product information
Active Ingredient and Strength | MEFENAMIC ACID - 250 MG |
Dosage Form | CAPSULE |
Manufacturer and Country | MICRO LABS LTD - INDIA |
Registration Number | SIN10125P |
Licence Holder | NAINA MOHAMED & SONS PRIVATE LIMITED |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | M01AG01 |
INDICATIONS AND USES:
Mefenamic acid capsules is used to relieve various types of pain such as: headache; body aches, rheumatoid arthritis, osteoarthritis; muscle and joint pains; toothache; sprains; painful menstruation (dysmenorrhea and menorrhagia); trauma-related pains.
DOSAGE AND ADMINISTRATION:
Undesirable effects may be minimized by using the minimum effective dose for the shortest duration necessary to control symptoms.
The oral dosage form of mefenamic acid may be taken with food if gastrointestinal upset occurs.
Mild to moderate pain/rheumatoid arthritis/osteoarthritis in adults and adolescents over 14 years of age: 500 mg three times daily.
Dysmenorrhea: 500 mg three times daily, to be administered at the onset of menstrual pain and continued while symptoms persist according to the judgment of the physician.
Menorrhagia: 500 mg three times daily, starting with the onset of bleeding and associated symptoms and continued according to the judgment of the physician.
CONTRAINDICATIONS:
Hypersensitivity to the active substance or any of the excipients
Inflammatory bowel disease.
History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy.
Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
Severe heart failure, hepatic failure and renal failure.
History of hypersensitivity reaction to other NSAIDs.
During the last trimester of pregnancy.
Treatment of pain after coronary artery bypass graft (CABG) surgery.